stat

JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.

ζ-Stat trisodium (NSC37044 trisodium) is a potent and selective inhibitor of protein kinase C-ζ (PKC-ζ), exhibiting an IC50 of 5 μM. It effectively suppresses the proliferation of melanoma cell lines and promotes apoptosis. Moreover, ζ-Stat trisodium demonstrates notable antitumor activity in vitro.

ζ-Stat (NSC37044), a specific and atypical inhibitor of PKC-ζ with an IC50 of 5 μM, demonstrates the ability to inhibit proliferation and induce apoptosis in melanoma cell lines, exhibiting antitumor activity in vitro[1][2].

STAT3-IN-B9 (B9) is an inhibitor of abnormal STAT3 activation and inhibits the proliferation of tumor cells including MDA-MB-468, MDA-MB-231, and DU145.

JAK2/STAT3-IN-1 is a GP130 inhibitor with anti-tumor effects and can be used to study inflammation, autoimmunity and cancer.

(R)-JAK2/STAT3-IN-10a is the R-isomer of JAK2/STAT3-IN-1.JAK2/STAT3-IN-1 is a GP130 D1 structural domain inhibitor with antitumor activity that inhibits the phosphorylation of JAK2 and STAT3. The KD value of (R)-JAK2/STAT3-IN-1 on GP130 protein is 3.8 μM.

STAT5-IN-1 (STAT5 Inhibitor) is a cell-permeable inhibitor which suppresses Stat5 via binding to the SH2 domain.

STAT3 Degrader-2 is a PROTAC-based compound that effectively reduces the total STAT3 protein levels, and is utilized in the research of cancer and various diseases [1].

PROTAC STAT3 degrader-2 is a selective and efficacious PROTAC degrader of STAT3 protein with a DC 50 of 3.54 μM in Molm-16 Cell. PROTAC STAT3 degrader-2 has the potential for cancer research [1] .

STAT3 Degrader-1 (Compound 295) is a potent degrader of STAT3, utilized in anticancer research [1].

STAT6-IN-2(R)-84 is a STAT6 inhibitor that inhibits eotaxin-3 secretion, induces STAT6 reporter luciferase activity in 293-EBNA cells, and inhibits tyrosine phosphorylation of STAT6.

STAT3-IN-1 selective and orally active inhibitor of STAT3(in HT29 and MDA-MB 231 cells, with IC50 values of 1.82 μM and 2.14 μM , respectively), induces tumor apoptosis.

STAT5-IN-2 is an inhibitor of STAT5 with antileukemic effects (EC50s: 9 μM and 5 μM in K562 and KU812 cells, respectively).

STAT3-IN-14 is a STAT3 inhibitor and has STAT3 phosphorylation inhibitory activity. STAT3-IN-14 can directly bind to the hinge region of STAT3 .

STAT3-IN-12 is a potent inhibitor of STAT3 signalling and inhibits IL-6-induced activation of the JAK/STAT3 signalling pathway. STAT3-IN-12 inhibits the growth and migration of cancer cells, blocks the cell cycle and induces apoptosis. HCC), oesophageal cancer.)

STAT3-IN-13 is a potent STAT3 inhibitor.STAT3-IN-13 has antiproliferative and anticancer activity and acts by binding to the structural domain of STAT3 SH2.STAT3-IN-13 inhibits the phosphorylation of STAT3 Y705, which induces apoptosis and inhibits tumor cell growth and metastasis.STAT3-IN-13 can be used to study breast cancer and liver cancer. The study of breast cancer and hepatocellular carcinoma.

α7 nAchR-JAK2-STAT3 agonist 1 is a potent inhibitor of the α7 nAchR-JAK2-STAT3 pathway that acts on nitric oxide (NO) (IC50: 0.32 μM). α7 nAchR-JAK2-STAT3 agonist 1 has been shown to have a positive effect on iNOS, IL-1β and IL-1β in murine macrophages RAW264.7. α7 nAchR-JAK2-STAT3 agonist 1 was effective in inhibiting the expression of iNOS, IL-1β and IL-6 in mouse macrophages. α7 nAchR-JAK2-STAT3 agonist 1 inhibited LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 agonist 1 was able to be used to study sepsis.

Stat3 (124H6) Mouse mAb #9139M is a useful organic compound for research related to life sciences and the catalog number is T64573.

STAT6-IN-3 (Compound 18a) serves as an inhibitor of STAT6 with an IC50 value of 44 nM, specifically targeting the Src Homology 2 (SH2) domain. It is utilized in research studies focused on inflammatory disorders, including asthma [1].

STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells and exhibits anti-proliferative properties. It promotes apoptosis by activating caspase-3 and elevating levels of cleaved polyADP-ribose polymerase, in addition to enhancing maturation and antigen presentation in dendritic cells. Moreover, STAT3-IN-18 has demonstrated in vivo safety.

STAT3-IN-20 (Compound 40), with an IC50 of 0.65 μM, is a selective inhibitor targeting the SH2 domain of STAT3, thereby impeding its phosphorylation, nuclear translocation, and subsequent gene transcription. The compound demonstrates antiproliferative effects on DU145 and MDA-MB-231 cancer cell lines, which have overactivated STAT3, with IC50 values of 2.97 μM and 3.26 μM, respectively. Moreover, STAT3-IN-20 induces cell cycle arrest and apoptosis [1].

STAT3-IN-10 (A11) is an inhibitor of STAT3 that directly binds to STAT3 SH2 domain, inhibits tumor cell growth and induces apoptosis in cancer cells (IC 50 = 5.18 μM) [1].

STAT3-IN-7, an orally active aryl sulfonamido azetidine compound, serves as a STAT3 inhibitor with anticancer activities.

STAT6-IN-1, a STAT6 inhibitor, exhibits high affinity for the SH2 domain of STAT6 (IC 50 = 0.028 µM), making it suitable for research on allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease, or cancer.

STAT3-IN-8 (compound H172) is a potent inhibitor of STAT3 with potential applications in cancer research [1].

STAT3-IN-11 is a selective STAT3 inhibitor with inhibitory effects on phosphorylation of the STAT3pTyr705 site and phosphorylation of Survivin.STAT3-IN-11 promotes apoptosis in cancer cells and is a candidate compound for the treatment of cancer.

STAT3-IN-9, a potent inhibitor of STAT3 activation at Tyr705, exhibits no impact on the phosphorylation of STAT1 at Tyr 701. Additionally, this compound efficiently induces apoptosis and cell cycle arrest specifically at the G2/M phase [1].

STAT3-IN-15, a potent and orally active inhibitor targeting STAT3, effectively combats idiopathic pulmonary fibrosis (IPF) by hindering STAT3 phosphorylation. Additionally, it impedes TGF-β1-induced migration and deformation of epithelial cells and prevents epithelial-mesenchymal transition (EMT), offering a multifaceted approach against IPF.

STAT3-IN-A69 is an inhibitor targeting the DNA-binding domain of STAT3, suppressing tumor growth, metastasis and STAT3 target gene expression in vivo.

Phospho-Stat3 (Tyr705) Antibody #9131R is a useful organic compound for research related to life sciences and the catalog number is T64629.

Epacadostat (INCB 024360) is an oral-available inhibitor of indoleamine 2, 3-dioxygenase (IDO1), increasing the proliferation and activation of various immune cells and reducing tumor-associated regulatory T cells.

Pevonedistat (MLN4924) is a potent and selective NEDD8 activating enzyme (NAE) inhibitor (IC50=4.7 nM). Pevonedistat can be used for the treatment of myelodysplastic syndromes (MDS) and also has antitumor activity.

Phorbol 12-myristate 13-acetate (PMA) belongs to the phorbol ester group of natural products and is an activator of PKC, SphK, and NF-κB. Phorbol 12-myristate 13-acetate induces THP1 cell differentiation.

Denifanstat (FASN-IN-2) is a Fatty Acid Synthase (FASN) inhibitor(IC50 of 0.052 μM and an EC50 of 0.072 μM),with potential antineoplastic activity.

Tucidinostat (Chidamide) is an effective and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, less active on HDAC8/11 (IC50: 733/432 nM), and shows no effect on HDAC4/5/6/7/9.

Telaglenastat (CB 839) (IC50 of 24 nM), an effective, specific, and oral inhibitor, which is bioavailable glutaminase, for recombinant human GAC.

Trichostatin A (TSA) is a natural derivative of diene isohydroxamic acids. Trichostatin A is a histone deacetylase inhibitor (IC50=1.8 nM) that is reversible and specific. Trichostatin A leads to the hyperacetylation of core histones, which regulates chromatin structure.

Valemetostat (DS-3201) is a first-in-class EZH1/2 dual inhibitor.

Osilodrostat (LCI699) (LCI699) is an effective inhibitor of human 11β-hydroxylase (IC50: 2.5 nM) and aldosterone synthase (IC50: 0.7 nM).

Liproxstatin-1 is a potent and selective inhibitor of ferroptosis (IC50=22 nM). Liproxstatin-1 protects cells from ferroptosis induced by ferroptosis inducers (e.g., Erastin, RSL3).

Necrostatin-1 (Nec-1) is a necrotic apoptosis inhibitor and RIP1 inhibitor with specificity. Necrostatin-1 inhibits TNF-α-induced necrotic apoptosis. Necrostatin-1 also inhibits IDO.

Tazemetostat (EPZ6438) is a histone methyltransferase EZH2 inhibitor (IC50=11 nM) that is orally active, selective, and SAM-competitive. Tazemetostat exhibits antitumor activity and may be used for the treatment of epithelioid sarcoma/follicular lymphoma.

Blebbistatin ((±)-Blebbistatin) is a selective non-muscle myosin II (NMII) inhibitor. It promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing. Furthermore it preserves cell junctional integrity and barrier function.Blebbistatin is an inhibitor of MYH9.

Ferrostatin-1 (Fer-1) is a potent and selective inhibitor of ferroptosis. Ferrostatin-1 potently inhibits Erastin-induced ferroptosis in HT-1080 cells with an EC50 of 60 nM. Ferrostatin-1 also exhibits antioxidant and antifungal activities.

Combretastatin A4 (CA4) is a microtubule-targeting agent that binds β-tubulin (Kd: 0.4 μM).

Methyl myristate (methyl tetradecanoate) is a natural product.

Panobinostat (NVP-LBH589) is a broad-spectrum HDAC inhibitor (IC50=5 nM) with oral activity and non-selectivity. Panobinostat has antitumor activity and induces apoptosis and autophagy.

Cholesterol Myristate (Cholesteryl Myristate) is a natural steroid found in traditional Chinese medicine that interacts with various ion channels, including the GABAA receptor, nicotinic acetylcholine receptor, and the inward-rectifier potassium ion channel.

Orlistat (Tetrahydrolipstatin) is an Intestinal Lipase Inhibitor. The mechanism of action of orlistat is as a Lipase Inhibitor.

Acetyl-Calpastatin (184-210)(human) acetate is a potent, selective and reversible calpain inhibitor with Ki values of 0.2 nM and 6 μM for µ-calpain and cathepsin L, respectively.